Talking Medicines joins 2026 UK AI Index

Tern plc

Talking Medicines has been named in the 2026 UK AI Index, placing it among the top 1,000 AI companies in the country.

The company’s core offering focuses on converting unstructured healthcare dialogue into structured, actionable intelligence for pharmaceutical clients. By applying natural language processing and machine learning to patient and healthcare professional conversations, Talking Medicines helps pharma teams improve how they position medicines, understand brand performance and engage with clinicians. This use of real-world voice data offers a practical solution to the ongoing challenge of making sense of fragmented health communications.

Recognition by the UK AI Index gives Talking Medicines a stronger position within a national network of AI companies that are attracting attention from both investors and policymakers. The index is supported by government and industry groups aiming to map out leadership in artificial intelligence across sectors such as health, finance and energy.

Tern plc (LON:TERN) backs exciting, high growth IoT innovators in Europe. They provide support and create a genuinely collaborative environment for talented, well-motivated teams.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Tern increases convertible loan note investment in Talking Medicines

Tern has received £270,000 of new unsecured convertible loan notes from Talking Medicines, increasing its total convertible loan note holding to approximately £0.79 million while retaining a 23.8% equity stake.

Tern Plc invests $280,000 in Device Authority convertible loan notes

Tern has invested $280,000 in new unsecured convertible loan notes issued by Device Authority, forming part of a wider funding round of up to $1.6 million from existing investors.

Surgical training technology moves closer to the centre of precision medicine

Fundamental XR is targeting a critical adoption gap in advanced healthcare by using immersive simulation to help surgical teams prepare for complex procedures with greater consistency and scale.

GLP-1 therapies move into a wider investor debate

GLP-1 therapies are moving beyond weight loss and diabetes, creating a wider investor discussion around behaviour, risk and market positioning.

Tern raises £222,000 through share placing

Tern has raised £222,000 before expenses through a placing of 37 million new ordinary shares at 0.60 pence per share, with admission to AIM expected on or around 22 May 2026.

FundamentalXR targets surgical readiness for advanced eye therapies

FundamentalXR is targeting surgical readiness for advanced eye therapies with immersive simulation designed to support real-world adoption.

Search